Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
Phase 1 A: First-in-human phase 1 study to determine safety of NP-G2-044 when given orally on a daily X 28 days followed by a 14 day rest period.
Breast Cancer|Pancreas Cancer|Prostate Cancer|Lung Cancer|Colon Cancer|Esophagus Cancer|Liver Cancer|Ovary Cancer|Advanced or Metastatic Treatment-refractory Solid Tumor Malignancies
DRUG: NP-G2-044
Establish the safe recommended phase 2 dose, Treatment related adverse events assessed by CTCAE V4.03, 24 months
Identify and characterize preliminary anti tumor activity, Anti tumor activity assessed using RECIST 1.1, 24 months|Characterize the pharmacokinetics of NP-G2-044, Drug exposure assessed by area under the curve (AUC), 24 months|Tmax, Time to peak plasma concentration, 24 months|Cmax, Peak plasma concentration, 24 months
Phase 1 A: First-in-human phase 1 study to determine safety of NP-G2-044 when given orally on a daily X 28 days followed by a 14 day rest period.